18 June 2021 - Deborah Wilkes
Premium
The US Food and Drug Administration (FDA) has approved the switch of Astepro (azelastine hydrochloride 0.15%) from prescription-to-OTC status. Bayer said its Astepro Allergy Nasal Spray would be available at national mass retail locations in the first quarter of 2022.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.